KRAS and non-small cell lung carcinoma: The exploratory analysis of KEYNOTE-042 showed that the first-line pembrolizumab monotherapy in patients with KRAS-mutant NSCLC has higher PFS (12 months vs. 6 months; HR = 0.51; 95% CI: 0.29-0.87) and OS (28 months vs. 11 months; HR = 0.42; 95% CI: 0.22-0.81) than platinum-containing chemotherapy (21).